Caspofungin: Clinical Trials

19 trials of Caspofungin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

16 completed, 2 terminated, 1 recruiting. 19 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 319Completed 16, Terminated 2, Recruiting 1
Phase 21Completed 1

Follow Caspofungin: new trials by email Literature Review of Caspofungin trials Research Report on Caspofungin

Trials (filtered) newest first · largest first

All 19 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
Fosmanogepix, Caspofungin, Fluconazole - Candidemia, Candidiasis, Invasive
Phase 3RecruitingBasilea Pharmaceutica4502024-12-112026-10-19
A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole
SCY-078, Fluconazole, Echinocandin - Candidiasis, Invasive, Candidemia
Phase 3TerminatedScynexis, Inc.682022-08-032026-08-10
Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis
Rezafungin for Injection, Caspofungin, Fluconazole - Candidemia, Mycoses
Phase 3CompletedCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)1992018-10-072023-01-06
Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant
Caspofungin Acetate, Fluconazole, Laboratory Biomarker Analysis - Fungal Infection, Hematopoietic and Lymphoid Cell Neoplasm
Phase 3CompletedChildren's Oncology Group2922013-03-212024-10-16
Empirical Versus Preemptive Antifungal Therapy
caspofungin acetate - Fungal Infection, Leukemia
Phase 3CompletedEuropean Organisation for Research and Treatment of Cancer - EORTC5562012-03-012023-12-11
Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia
Caspofungin Acetate, Fluconazole, Laboratory Biomarker Analysis - Acute Myeloid Leukemia, Adult Acute Monoblastic Leukemia
Phase 3CompletedChildren's Oncology Group5172011-04-042021-03-30
Liver Transplant European Study Into the Prevention of Fungal Infection
micafungin, fluconazole, liposomal amphotericin B - Liver Transplantation, Mycoses
Phase 3CompletedAstellas Pharma Inc3502009-12-152024-11-18
Pharmacokinetics of Caspofungin in Burn Patients
Caspofungin (drug) - Thermal Injury
Phase 2 / Phase 3CompletedAssistance Publique - Hôpitaux de Paris22009-02-012026-03-04
A Clinical Study of MK0991 (Caspofungin) in Japanese Patients With Deep-seated Candida or Aspergillus Infections (0991-062)(COMPLETED)
caspofungin acetate, Comparator: Micafungin sodium - Fungal Infection
Phase 3CompletedMerck Sharp & Dohme LLC1212008-08-012017-03-23
A Study of Caspofungin Acetate (MK0991) for the Treatment of Esophageal Candidiasis or Invasive Candidiasis in Chinese Adults (MK-0991-066)
caspofungin acetate - Fungal Infection
Phase 3CompletedMerck Sharp & Dohme LLC632008-01-012017-03-24
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
Isavuconazole, Caspofungin, Voriconazole - Candidiasis, Invasive, Candidemia
Phase 3CompletedAstellas Pharma Inc4502007-03-082024-12-10
Evaluate the Safety and Efficacy of Caspofungin Acetate as Empirical Therapy in Chinese Adults With Persistent Fever and Neutropenia (0991-055)
MK0991, caspofungin acetate / Duration of Treatment: - Fungal Infection
Phase 3CompletedMerck Sharp & Dohme LLC1312006-03-012015-12-17
A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)
caspofungin acetate - Invasive Candidiasis
Phase 3CompletedMerck Sharp & Dohme LLC2042006-01-012017-03-24
A 28 - 90 Days Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Injection as Empirical Therapy in Indian Adults With Persistent Fever and Neutropenia (0991-053)(COMPLETED)
caspofungin acetate - Fungal Infection
Phase 3CompletedMerck Sharp & Dohme LLC502005-06-012017-02-23
Caspofungin to Prevent Candidiasis in Adults in Hospital Intensive Care Units
Caspofungin - Candidiasis
Phase 3CompletedNational Cancer Institute (NCI)12002004-12-012008-03-04
Caspofungin Study for Fungal Infections in Adults in Critical Care Settings
Caspofungin, Placebo - Candidiasis
Phase 3TerminatedNational Institute of Allergy and Infectious Diseases (NIAID)12002004-10-012014-12-05
Study of Micafungin in Patients With Invasive Candidiasis or Candidemia
Micafungin, Caspofungin - Candidiasis, Candidemia
Phase 3CompletedAstellas Pharma Inc6112004-09-012014-09-18
Trial of Two Dosing Regimens of Micafungin Versus Caspofungin for the Treatment of Esophageal Candidiasis
micafungin, caspofungin - Candidiasis, Oral
Phase 3CompletedAstellas Pharma Inc4542004-06-012014-08-20
Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment
caspofungin acetate, liposomal amphotericin B - Cancer
Phase 3CompletedMemorial Sloan Kettering Cancer Center2000-08-012013-01-18

Conditions studied

Mycoses (13)  ·  Candidemia (5)  ·  Candidiasis, Invasive (5)  ·  Candidiasis (4)  ·  Invasive Fungal Infections (4)  ·  Leukemia, Myeloid, Acute (3)  ·  Leukemia (2)  ·  Neutropenia (2)  ·  Torulopsis (2)  ·  Blast Crisis (1)  ·  Breast Neoplasms (1)  ·  Burkitt Lymphoma (1)  ·  Candidiasis, Oral (1)  ·  Carcinoma, Embryonal (1)  ·  Carcinoma, Ovarian Epithelial (1)

Sponsors

Merck Sharp & Dohme LLC (5)  ·  Astellas Pharma Inc (4)  ·  Children's Oncology Group (2)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Basilea Pharmaceutica (1)  ·  Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1)  ·  European Organisation for Research and Treatment of Cancer - EORTC (1)  ·  Memorial Sloan Kettering Cancer Center (1)  ·  National Cancer Institute (NCI) (1)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (1)  ·  Scynexis, Inc. (1)

Countries

United States (10)  ·  France (8)  ·  Belgium (7)  ·  Germany (7)  ·  Spain (6)  ·  Canada (5)  ·  Italy (5)  ·  Argentina (4)  ·  Brazil (4)  ·  China (4)  ·  Israel (4)  ·  South Africa (4)  ·  Australia (3)  ·  Austria (3)  ·  Bulgaria (3)

Top investigators

Alexandra Hill, MD (1)  ·  Christophe Vinsonneau, MD (1)  ·  Christopher C Dvorak (1)  ·  David Angulo, MD (1)  ·  Kent Sepkowitz, MD (1)  ·  Taylor Sandison, MD, MPH (1)  ·  Theoklis E Zaoutis (1)

Results publications

PMID 15459300, PMID 21147825, PMID 22585216, PMID 23052987, PMID 23959319, PMID 25520332, PMID 25902926, PMID 30289478, PMID 31688884, PMID 33136159, PMID 33438477, PMID 35906831, PMID 36442484, PMID 38008099, PMID 38502709, PMID 38985561, PMID 39259571, PMID 39468640, PMID 39529079, PMID 41194465, PMID 41940006

NIH funding

U10CA095861 (2), UG1CA189955 (2), 2008 (1)